Vaxxinity is developing the first multitope peptide-based vaccine for COVID-19 and has a commercial antibody test available under US FDA EUA. The vaccine candidate activates both an antibody response and a T-cell response to SARS-CoV-2 for robust protection.
Vaxxinity innovates cutting-edge treatment and prevention strategies for neurological disease including Alzheimer’s and Parkinson’s. These Vaxxines are well tolerated and administered infrequently, going where monoclonal antibodies cannot.
Vaxxines for well validated targets in highly prevalent chronic diseases such as migraine and hypercholesterolemia may have disruptive advantages over monoclonal and small molecule approaches, including safety, convenience, cost effectiveness, and accessibility.
Vaxxinity’s proven, innovative platform has the power to activate different arms of the immune system selectively, and to neutralize targets with high specificity
Vaxxinity will be a newly formed entity merging United Neuroscience and COVAXX, both spinouts of the United Biomedical Group
The body’s immune system is the best defense against disease. With its peptide-based platform, Vaxxinity “programs” the immune system for an effective response against a potentially broad set of indications, both chronic and infectious. Vaxxines can break immune tolerance to turn the body into an “antibody factory,” far more cost effective than developing and producing monoclonals.
Vaxxinity is focused on rapidly developing the first multitope peptide-based vaccine for COVID-19. Our approach is to utilize the clinically and commercially proven UBITh peptide vaccine platform to develop a high precision COVID-19 vaccine.
Learn how next-generation #vaccine manufacturers are seizing on an unprecedented regulatory momentum. Join Christina Yi of Vaxxinity & @MattPillar of BioProcess Online on Apr. 13 at 11 AM ET for Manufacturing Vaccines On COVID's Coattails. Register here: https://t.co/f2SwyfPW5I
Our co-founders Mei Mei Hu and Lou Reese have taken a global approach to COVID-19 #vaccine development. Our team has tracked the spread of the virus to prioritize nations with an overwhelming unmet need for COVID-19 vaccines. Learn more at . https://t.co/cScUCKgydP
We have exciting news! Today we announce the merging of United Neuroscience & COVAXX to form Vaxxinity. Vaxxinity will continue our mission to develop its COVID-19 & neurological diseases vaccines for global distribution. View the news release here: https://t.co/DxtAq0Dbaj
This @Newsday article by @kschach profiles COVAXX’s Long Island roots along with our global approach to vaccine development & distribution. Read more here:
Learn how COVAXX is taking a novel approach to developing our #COVID19 vaccine candidate, UB-612, in this @ScienceNews article by @thsaey.
This @FinancialTimes article lays out COVAXX’s plans to leverage its COVID-19 vaccine distribution agreement with @Maersk. The partnership aims to increase efficiency of vaccine delivery using ships. Read the full story by @harrydemps here:
RECAP: @theedgemalaysia spotlighted our COO, Christina Yi, and other leaders in the #COVID19 vaccine manufacturing space at the recent COVID-19 Vaccine Summit on Global Access & Distribution Makers and Movers 2021. Read more here:
Our COO Christina Yi recently participated in the Makers & Movers 2021 Covid-19 Vaccine Summit to detail how COVAXX plans to tackle the challenges of global access and distribution of our COVID-19 #vaccine candidate UB-612. Watch here:
This @WIRED article by Jared Whitlock explores COVAXX’s international Phase II/III clinical trial design for UB-612. COVAXX has taken an international approach with operations in both the U.S. & Taiwan & clinical trials starting in Brazil.
Happy International Women’s Day! COVAXX celebrates the #WomenInStem who make up 50% of our team. We are proud to foster a culture of inclusivity and equality at COVAXX, all under the leadership of our CEO Mei Mei Hu. https://t.co/nfRCFpgFRC